Skip to search formSkip to main contentSkip to account menu

ISCOMATRIX

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2012
Review
2012
The ISCOMATRIX adjuvant has antigen delivery and presentation properties as well as immunomodulatory capabilities, which combine… 
2010
2010
ISCOMATRIX™ adjuvant is a component of a variety of developmental vaccines. To evaluate the safety profile of ISCOMATRIX… 
Review
2009
Review
2009
Highly Cited
2009
Highly Cited
2009
Cancer vaccines aim to induce antitumor CTL responses, which require cross-presentation of tumor Ag to CTLs by dendritic cells… 
Review
2009
Review
2009
Adjuvants are components that when added to subunit antigen (Ag) vaccines boost their immunogenicity and thus immune efficacy… 
Review
2007
Review
2007
The ISCOMATRIX™ adjuvant has antigen-delivery and -presentation properties, as well as immunomodulatory capabilities that combine… 
Highly Cited
2005
Highly Cited
2005
Dendritic cells (DCs) are being evaluated for cancer immunotherapy due to their unique ability to induce tumor-directed T-cell… 
Highly Cited
2004
Highly Cited
2004
NY-ESO-1 is a "cancer-testis" antigen expressed in many cancers. ISCOMATRIX is a saponin-based adjuvant that induces antibody and…